Live Breaking News & Updates on Malignant Hematology|Page 3
Stay updated with breaking news from Malignant hematology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in patients with triple-class–exposed, relapsed/refractory multiple myeloma, highlighting an analysis of cytopenias and infections in patients from the phase 3 KarMMa-3 trial. ....
Andrew Kuykendall, MD, discusses the efficacy of the combination of pelabresib and ruxolitinib in patients with JAK inhibitor–naive myelofibrosis based on data from the phase 3 MANIFEST-2 trial. ....
David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia. ....
Long-term cancer survivors experience diabetes at similar rates as individuals who are cancer-free, but cancer survivors with diabetes face a potentially higher risk of death, researchers have found. ....
Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial. ....